MedTrace Logo

Safety and Tolerability of NN9068 in Healthy Male Volunteers

NCT00983021 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-02-08

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068.

The trial participants will be randomised to 4 different treatments in trial, receiving trial products in a pre-defined order.

Conditions

Interventions

DRUG

insulin degludec/liraglutide

Single, simultaneous dose of NN9068, injected s.c. (under the skin)

DRUG

insulin degludec

Single, simultaneous dose of NN1250, injected s.c. (under the skin)

DRUG

liraglutide

Single, simultaneous dose of NN2211, injected s.c. (under the skin)

DRUG

placebo

Single, simultaneous dose of placebo, injected s.c. (under the skin)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00983021 on ClinicalTrials.gov